FLUniversal is a consortium of 8 academic and industry partners advancing the development of a universal influenza vaccine with a €7.6 million grant from the European Union. We are implementing clinical trials of DeltaFLU, a rapid-acting universal influenza vaccine for intranasal administration. Our consortium is developing a novel controlled human infection model (CHIM) to evaluate protective efficacy of DeltaFLU in a clinical challenge study. We also seek to elucidate molecular and immunological mechanisms of protection, and to identify potential new correlates of protection using data from our clinical trials and preclinical models. This project has received funding under the European Union's Horizon Europe research and innovation program under grant agreement No 101080692. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
External link for FLUniversal
Funded by the EU, the FLUniversal consortium is advancing development of Vivaldi Biosciences' DeltaFLU universal #influenza #vaccine in clinical trials using cutting-edge immunological analyses.
Advantages of nasal-spray #vaccines and how they work are described here. Vivaldi's DeltaFLU universal #influenza vaccine is in development as the first nasal-spray vaccine that protects against all influenza virus strains. https://lnkd.in/ei8kGe23
FLUniversal Member Profile: Zafiro Business Solutions Zafiro Business Solutions Ltd. is a European consulting firm specializing in Horizon Europe and other R&D grant projects. Beyond grant consulting and proposal writing, the firm offers comprehensive business consulting services, including market analysis, commercialization planning, business case development, cost-benefit analysis, business plan preparation, IP protection, and company valuation. Additionally, they provide legal and financial management support for beneficiaries of EU funding. For FLUniversal, Zafiro serves as the Coordinator responsible for Project Management activities. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal Member Profile: MediTox MediTox s.r.o. (Konárovice, Czech Republic) is a GLP-certified contract research organization dedicated to preclinical research and development in partnership with industry and academic institutes. MediTox has expertise in conducting a broad range of exploratory, proof of concept and regulatory experiments in full compliance with GLP standards and international guidelines. MediTox has extensive experience with the ferret model of influenza, which closely resembles influenza infection and immunity in humans. For FLUniversal, MediTox is responsible for preclinical evaluations of DeltaFLU universal influenza vaccine in the ferret model, providing data on immune responses, viral parameters and general toxicity. MediTox also will evaluate efficacy of DeltaFLU in immunized ferrets challenged with wild-type influenza viruses. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal Member Profile: Medicines and Healthcare products Regulatory Agency The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is an Associated Partner in the FLUniversal consortium. MHRA regulates medicines, medical devices, and blood components for transfusion in the UK. MHRA also is the leading World Health Organization (WHO) Collaborating Centre and International Laboratory for Biological Standards, and one of four WHO Essential Regulatory Laboratories for influenza. With extensive experience in virus characterization and access to critical reagents, assays and models, MHRA supports FLUniversal in evaluation and selection of the influenza virus strain for the controlled human infection model to evaluate preliminary efficacy of DeltaFLU universal influenza vaccine in healthy volunteers. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal Member Profile: VisMederi VisMederi Research Srl SRL (Siena, Italy) is a research and qualified services company with expertise in analytical testing of biological samples and validation of bioanalytical methods for the biopharma industry and public health. VisMederi has particular strengths in optimization of assays for the evaluation of serological and cellular immune response, and as well as development of specific methods aimed at efficacy and immunogenicity studies. VisMederi’s unique competence in GCLP-accredited qualified sample analysis provides a vital contribution to evaluation of the immune response and protective efficacy of DeltaFLU universal influenza vaccine. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal reposted this
We thank our FLUniversal colleagues for an informative and constructive meeting. We especially thank Dr. Ed Schmidt and Leiden University Medical Center for organising and hosting the meeting.
We are thrilled to announce that the FLUniversal consortium held its first annual meeting in Leiden on 25-27 June 2024. FLUniversal brings together experts from across the EU to advance clinical development of the DeltaFLU universal influenza vaccine and to build knowledge about immune mechanisms of protection against influenza. The event, hosted by FLUniversal consortium member Leiden University Medical Center, was a resounding success. It brought together our dedicated team, stakeholders, and partners to review progress, share insights, and chart the path forward. Discussions were productive and enlightening, showcasing the impact made over the past year and setting ambitious goals for the future. Thanks to everyone who participated and contributed to the success of this meeting. Here's to another year of innovation, collaboration, and transformative growth! (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
What a wonderful building with great people there! Was a great experience seeing how Ingrid de Visser-Kamerling and her team contribute to the success of Fluniversal project.
FLUniversal held a highly successful Annual General Meeting in Leiden in June 2024. A highlight of the event was a visit to the Centre for Human Drug Research (CHDR), a distinguished member of our Consortium. CHDR, an independent institute renowned for its early-stage clinical drug research, welcomed us warmly and provided a tour of their cutting-edge laboratories and research units where the Consortium will run clinical trials of the DeltaFLU universal influenza vaccine. Including the brand-new infection unit, where Ingrid de Visser - Kamerling and her team executes controlled human infection studies (CHIM studies) to test new vaccines and therapeutics against infectious diseases. With state-of-the-art facilities and comprehensive in-house services, including analytical labs, data management, and regulatory affairs, CHDR truly impressed our participants. We are deeply grateful to CHDR for their hospitality and for showcasing their remarkable contributions to the field. The visit was not only informative but also inspiring, reinforcing the innovative spirit and collaborative ethos of our Consortium. Thank you to everyone who attended and made this AGM a memorable event. We look forward to continuing our collaborative journey towards groundbreaking advancements in vaccine research. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal held a highly successful Annual General Meeting in Leiden in June 2024. A highlight of the event was a visit to the Centre for Human Drug Research (CHDR), a distinguished member of our Consortium. CHDR, an independent institute renowned for its early-stage clinical drug research, welcomed us warmly and provided a tour of their cutting-edge laboratories and research units where the Consortium will run clinical trials of the DeltaFLU universal influenza vaccine. Including the brand-new infection unit, where Ingrid de Visser - Kamerling and her team executes controlled human infection studies (CHIM studies) to test new vaccines and therapeutics against infectious diseases. With state-of-the-art facilities and comprehensive in-house services, including analytical labs, data management, and regulatory affairs, CHDR truly impressed our participants. We are deeply grateful to CHDR for their hospitality and for showcasing their remarkable contributions to the field. The visit was not only informative but also inspiring, reinforcing the innovative spirit and collaborative ethos of our Consortium. Thank you to everyone who attended and made this AGM a memorable event. We look forward to continuing our collaborative journey towards groundbreaking advancements in vaccine research. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
We are thrilled to announce that the FLUniversal consortium held its first annual meeting in Leiden on 25-27 June 2024. FLUniversal brings together experts from across the EU to advance clinical development of the DeltaFLU universal influenza vaccine and to build knowledge about immune mechanisms of protection against influenza. The event, hosted by FLUniversal consortium member Leiden University Medical Center, was a resounding success. It brought together our dedicated team, stakeholders, and partners to review progress, share insights, and chart the path forward. Discussions were productive and enlightening, showcasing the impact made over the past year and setting ambitious goals for the future. Thanks to everyone who participated and contributed to the success of this meeting. Here's to another year of innovation, collaboration, and transformative growth! (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)
FLUniversal Member Profile: Statens Serum Institut Statens Serum Institut (SSI, Copenhagen, Denmark), under the auspices of the Danish Ministry of Health, is responsible for preparedness against infectious diseases and biological threats. SSI’s expertise in vaccine research includes identification and evaluation of antigens using genomic and proteomic techniques, development of novel adjuvants, and the study of disease transmission, infection, immune response, and protection in animal models. With its unique experience with the Syrian golden hamster model, SSI will make important contributions to FLUniversal program objectives in conducting detailed analyses of antibody and cellular immune responses to intranasal immunization with DeltaFLU universal influenza vaccine and identifying correlates of protection. (Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.)